ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.911,87
0,07%
S&P 500
5.996,66
1,00%
Dow Jones
43.487,83
0,78%
Euro vs US Dollar
1,03134
0,35%
Bitcoin
108.539,71
5,26%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) News

REPL

Replimune (REPL)

Replimune Group Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:REPL
DatumZeitQuelleÜberschriftSymbolFirma
17/01/202523h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
10/01/202522h01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
08/01/202514h00GlobeNewswire Inc.Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsNASDAQ:REPLReplimune Group Inc
23/12/202414h00GlobeNewswire Inc.Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REPLReplimune Group Inc
20/12/202423h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
19/12/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
16/12/202422h48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REPLReplimune Group Inc
04/12/202414h30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:REPLReplimune Group Inc
27/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
26/11/202423h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:REPLReplimune Group Inc
26/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
26/11/202405h55GlobeNewswire Inc.Replimune Announces Pricing of Upsized Public OfferingNASDAQ:REPLReplimune Group Inc
25/11/202413h09GlobeNewswire Inc.Replimune Announces Proposed Public OfferingNASDAQ:REPLReplimune Group Inc
21/11/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
21/11/202422h05GlobeNewswire Inc.Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNASDAQ:REPLReplimune Group Inc
21/11/202403h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
21/11/202403h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
19/11/202423h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
14/11/202413h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:REPLReplimune Group Inc
12/11/202414h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REPLReplimune Group Inc
12/11/202414h00GlobeNewswire Inc.Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
09/11/202419h00GlobeNewswire Inc.Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)NASDAQ:REPLReplimune Group Inc
08/11/202422h01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
30/10/202414h15GlobeNewswire Inc.Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:REPLReplimune Group Inc
16/10/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
09/10/202422h01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
01/10/202414h00GlobeNewswire Inc.Replimune to Present at Two Upcoming Investor ConferencesNASDAQ:REPLReplimune Group Inc
15/09/202415h45GlobeNewswire Inc.Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
09/09/202414h00GlobeNewswire Inc.Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024NASDAQ:REPLReplimune Group Inc
05/09/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
 Showing the most relevant articles for your search:NASDAQ:REPL

Kürzlich von Ihnen besucht

CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
COIN
SOLUSD
Solana
FX
EURJPY
Euro vs Yen
TG
BAS
BASF
NASDAQ
GOOGL
Alphabet
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
DBI
SDXP
SDAX
TG
BAYN
Bayer
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten